SCHEMBL32688294

SCHEMBL32688294

N#Cc1c(-c2ccc(Cl)cc2Cl)nc(=O)[nH]c1SCc1nnn[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.41
▸ KMT2A Q03164 5/20 0.41
▸ HPGD P15428 2/20 0.41
▸ LMNA P02545 2/20 0.41
▸ GAA P10253 1/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ CA12 O43570 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ CA9 Q16790 1/20 0.40
▸ POLB P06746 4/20 0.40
▸ USP2 O75604 1/20 0.40
▸ ALOX12 P18054 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ MAPT P10636 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ CA5A P35218 1/20 0.36
▸ MET P08581 2/20 0.35
▸ EGFR P00533 1/20 0.35
▸ CDK4 P11802 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32688228 0.88 HSD11B1 (0.40) MEN1KMT2AHPGDKDM4EPOLB
SCHEMBL32688043 0.86 LMNA (0.45) MEN1KMT2ALMNACA12CA2
SCHEMBL32688157 0.84 MEN1 (0.46) MEN1KMT2APOLBHSD11B1
SCHEMBL32687967 0.83 MEN1 (0.43) MEN1KMT2ALMNACA12CA2
SCHEMBL32688366 0.81 ACMSD (0.47) MEN1KMT2AHPGDPOLBMAPT
SCHEMBL32688407 0.80 ACMSD (0.39) MEN1KMT2AHPGDLMNAPOLB
SCHEMBL32688268 0.79 MEN1 (0.42) MEN1KMT2AHPGDLMNACA12
SCHEMBL32688267 0.77 ADORA1 (0.40) MEN1KMT2AHPGDLMNAKDM4E
SCHEMBL32688144 0.77 MEN1 (0.48) MEN1KMT2AHPGDLMNAKDM4E
SCHEMBL32688285 0.77 POLB (0.40) MEN1KMT2ALMNACA12CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078105-A1 Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors ORSOBIO INC (US) 2026-03-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078105-A1 Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors CPT1B, CBR1, MUSK MEN1 4353/4885KMT2A 3400/4885HPGD 431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback